CRDF
Cardiff Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.39
+6.92%2
Insider buys (3m)
0
Insider sells (3m)
$1.0M
Net value (3m)
+1.2%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jul 16, 2026 | PACE GARY W · director | Purchase | 687,285 | $1.46 |
| Jul 16, 2026 | Mohindru Mani · director, officer: Chief Executive Officer | Purchase | 34,364 | $1.46 |
| Jun 22, 2026 | Mohindru Mani · director, officer: Chief Executive Officer | Purchase | 24,703 | $1.21 |
| Jun 22, 2026 | PACE GARY W · director | Purchase | 30,000 | $1.22 |
| Jun 15, 2026 | Armitage James O · director | A-Award | 40,565 | $1.59 |
| Jun 15, 2026 | White Lale · director | A-Award | 40,565 | $1.59 |
| Jun 15, 2026 | TANNENBAUM RENEE P · director | A-Award | 40,565 | $1.59 |
| Jun 15, 2026 | Markin Rodney S · director | A-Award | 40,565 | $1.59 |
| Jun 15, 2026 | PACE GARY W · director | A-Award | 40,565 | $1.59 |
| Apr 28, 2026 | Aggarwal Ajay · officer: Chief Operating Officer | A-Award | 400,000 | $1.72 |
| Apr 16, 2026 | Smeal Tod · officer: Chief Scientific Officer | A-Award | 300,000 | $1.63 |
| Apr 16, 2026 | Muntner Joshua B · officer: Chief Financial Officer | A-Award | 486,650 | $1.58 |
| Apr 2, 2026 | Mohindru Mani · director, officer: Chief Executive Officer | A-Award | 600,000 | $1.62 |
| Feb 18, 2026 | Mohindru Mani · director, officer: Interim CEO | A-Award | 200,000 | $1.56 |
| Feb 18, 2026 | Lindsay Brigitte Ute · officer: Chief Accounting Officer | A-Award | 200,000 | $1.60 |
| Jul 31, 2025 | PACE GARY W · director | Purchase | 275,000 | $2.45 |
| Jul 31, 2025 | PACE GARY W · director | Purchase | 15,000 | $2.45 |
| Jun 30, 2025 | Markin Rodney S · director | A-Award | 40,565 | $3.16 |
| Jun 30, 2025 | TANNENBAUM RENEE P · director | A-Award | 40,565 | $3.16 |
| Jun 30, 2025 | Mohindru Mani · director | A-Award | 40,565 | $3.16 |
| Jun 27, 2025 | Armitage James O · director | A-Award | 40,565 | $3.16 |
| Jun 27, 2025 | White Lale · director | A-Award | 40,565 | $3.16 |
| Jun 27, 2025 | PACE GARY W · director | A-Award | 40,565 | $3.16 |
| Mar 13, 2025 | Levine James E. · officer: Chief Financial Officer | A-Award | 332,621 | $3.58 |
| Mar 13, 2025 | Kabbinavar Fairooz · officer: Chief Medical Officer | A-Award | 150,000 | $3.58 |
| Mar 13, 2025 | Smeal Tod · officer: Chief Scientific Officer | A-Award | 332,621 | $3.58 |
| Mar 13, 2025 | Erlander Mark · director, officer: Chief Executive Officer | A-Award | 758,400 | $3.58 |
| Dec 18, 2024 | Levine James E. · officer: Chief Financial Officer | Purchase | 2,564 | $3.83 |
| Dec 18, 2024 | Levine James E. · officer: Chief Financial Officer | Purchase | 2,752 | $5.42 |
| Dec 18, 2024 | Levine James E. · officer: Chief Financial Officer | Purchase | 2,400 | $5.00 |
Institutional positioning
13F filings over the trailing two quarters
New 43Increased 62Reduced 69Sold out 31
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BLACKROCK, INC. | Reduced | 3,981,387 | May 13, 2026 |
| Laurion Capital Management LP | Increased | 3,098,299 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 2,895,592 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 2,855,966 | May 15, 2026 |
| LAURION CAPITAL MANAGEMENT LP | Reduced | 2,646,738 | May 14, 2026 |
| PFIZER INC | Unchanged | 2,411,575 | May 12, 2026 |
| PFIZER INC | Unchanged | 2,411,575 | Aug 13, 2026 |
| ACORN CAPITAL ADVISORS, LLC | Reduced | 1,762,084 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 1,599,663 | May 15, 2026 |
| FRANKLIN RESOURCES INC | Unchanged | 1,205,803 | May 13, 2026 |
| FRANKLIN RESOURCES INC | Unchanged | 1,205,803 | Aug 13, 2026 |
| STATE STREET CORP | Reduced | 1,186,947 | May 15, 2026 |
| BlackRock, Inc. | Reduced | 972,873 | Aug 7, 2026 |
| BLAIR WILLIAM & CO/IL | Reduced | 922,407 | May 8, 2026 |
| BLAIR WILLIAM & CO/IL | Reduced | 912,513 | Aug 11, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jul 16, 2026